{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:41:20Z","timestamp":1775947280991,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease usually treated with immunomodulatory\/immunosuppressive agents. The use of these agents has been associated with an increased susceptibility to infections. Vaccination might represent a critical aspect in the management of patients with psoriasis treated with immunomodulatory\/immunosuppressive therapies. This narrative review aimed to provide an overview on the immune response to vaccines in subjects treated with systemic agents used to treat patients with moderate to severe psoriasis. Publications appearing in PubMed, Scopus, and ISI\u2013Web of Knowledge database were selected using Medical Subject Headings key terms. Overall, published data confirmed that vaccination with attenuated live vaccines during therapy with immunomodulatory\/immunosuppressive therapies should be avoided. For nonlive vaccines, a more favorable safety profile of biologic agents compared to conventional systemic agents is described as the humoral response to vaccines is in general well-preserved. Treatment with cyclosporine and methotrexate is associated with lower antibody titers to vaccines, and thus these agents are better discontinued during vaccination. In contrast, treatment with biological agents is not associated with lower antibody response and can thus be continued safely.<\/jats:p>","DOI":"10.3390\/vaccines8040769","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T09:21:15Z","timestamp":1608110475000},"page":"769","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"first","affiliation":[{"name":"Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Dermatologia, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":false,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Keller","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","article-title":"Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom","volume":"138","author":"Takeshita","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"BIOBADADERM Study Group. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry","volume":"137","author":"Dauden","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2020.16866","article-title":"COVID-19 and mRNA Vaccines-First Large Test for a New Approach","volume":"324","author":"Abbasi","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1203475418811347","article-title":"Practical Guidelines for Managing Patients with Psoriasis on Biologics: An Update","volume":"23","author":"Poelman","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1074-7613(02)00391-6","article-title":"Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses","volume":"17","author":"Nakae","year":"2002","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cyto.2012.03.018","article-title":"Th17 cell-derived IL-17 is dispensable for B cell antibody production","volume":"59","author":"Shibui","year":"2012","journal-title":"Cytokine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/ar3808","article-title":"Vaccination under TNF blockade\u2014Less effective, but worthwhile","volume":"14","author":"Aringer","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1186\/ar3542","article-title":"Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor","volume":"13","author":"Kobie","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00915009","article-title":"The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans","volume":"5","author":"Palestine","year":"1985","journal-title":"J. Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-198610000-00009","article-title":"Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine","volume":"42","author":"Versluis","year":"1986","journal-title":"Transplantation"},{"key":"ref_18","first-page":"e409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"Howard","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10067-013-2483-0","article-title":"Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis","volume":"33","author":"Kogure","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s13075-014-0506-0","article-title":"Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases","volume":"16","author":"McMahan","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","first-page":"898","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","article-title":"Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs","volume":"30","author":"Kapetanovic","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"ref_30","unstructured":"Patel, D., Maczuga, S., Helm, M.F., and Foulke, G.T. (2020). A retrospective cohort study confirms that prophylactic vaccination is underutilized in patients on tumor necrosis factor inhibitors. J. Am. Acad. Dermatol., 32182\u201332184."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Al-Omar, H.A., Sherif, H.M., and Mayet, A.Y. (2019). Vaccination status of patients using anti-TNF therapy and the physicians\u2019 behavior shaping the phenomenon: Mixed-methods approach. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223594"},{"key":"ref_32","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1086\/338043","article-title":"Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus","volume":"34","author":"Elkayam","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: Results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_35","first-page":"S90","article-title":"Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): Results of a phase 3 multicenter clinical trial","volume":"44","author":"Mease","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_36","first-page":"1356","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_37","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_38","first-page":"1122","article-title":"Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use","volume":"12","author":"Brodmerkel","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40259-017-0249-y","article-title":"Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants","volume":"31","author":"Gomez","year":"2017","journal-title":"BioDrugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/CVI.00386-12","article-title":"Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomized single-center study","volume":"19","author":"Chioato","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e001018","DOI":"10.1136\/rmdopen-2019-001018","article-title":"Secukinumab does not impair the immunogenic response to the influenza vaccine in patients","volume":"5","author":"Richi","year":"2019","journal-title":"RMD Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.vaccine.2019.10.081","article-title":"Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab","volume":"38","author":"Furer","year":"2020","journal-title":"Vaccine"},{"key":"ref_43","first-page":"837","article-title":"Influenza vaccination rate among patients with moderate to severe psoriasis","volume":"11","author":"Radtke","year":"2013","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10067-008-1007-9","article-title":"Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors","volume":"28","author":"Fuchs","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jid.2018.09.012","article-title":"Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases","volume":"139","author":"Noe","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"258430","DOI":"10.1155\/2015\/258430","article-title":"Possible Triggering Effect of Influenza Vaccination on Psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/15569527.2012.727936","article-title":"Psoriasis triggered by tetanus-diphtheria vaccination","volume":"32","author":"Macias","year":"2013","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5021\/ad.2013.25.4.489","article-title":"New Onset Guttate Psoriasis Following Pandemic H1N1 Influenza Vaccination","volume":"25","author":"Shin","year":"2013","journal-title":"Ann. Dermatol."},{"key":"ref_49","first-page":"684","article-title":"New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy","volume":"7","author":"Dudelzak","year":"2008","journal-title":"J. Drugs Dermatol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/769\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:45:59Z","timestamp":1760179559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040769"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040769","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}